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A B S T R A C T
In total, 177 patients with bloodstream infections caused by Staphylococcus aureus (BSISA) were
investigated prospectively between June 1999 and June 2001. Of these, 19.8% had community-acquired
BSISA, while 80.2% had nosocomial BSISA. Surgical intervention, foreign body, mechanical ventilation,
total parenteral nutrition, and previous antibiotic treatment were found to be important risk factors for
the nosocomial BSISA group. Secondary BSISA formed a greater proportion (62.9%) of community-
acquired infections than of nosocomial infections (26.8%; p 0.0001). Catheter-related nosocomial BSISA
was observed in 72.1% of patients. The suppurative complication rate was significantly higher among
community-acquired infections (22.9%) than among nosocomial infections (6.3%; p 0.008). Of the
nosocomial BSISA, 65.5%were methicillin-resistant. Analysis of 80 methicillin-resistant S. aureus isolates
by pulsed-field gel electrophoresis identified ten main clones (A–J), but 61 (76.3%) of the 80 isolates
belonged to clone A.
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I N T R O D U C T I O N
Staphylococci are among the most important
causes of both hospital- and community-acquired
infections worldwide [1–3]. Staphylococcus aureus
causes superficial and deep skin and soft tissue
infections, bacteraemia with metastatic abscess
formation, and a variety of toxin-mediated infec-
tions, including gastroenteritis, staphylococcal
scalded skin syndrome and toxic shock syndrome
[2,4–7]. In the early 1980s, a change in the
spectrum of nosocomial pathogens became appar-
ent, as Gram-positive cocci began to re-emerge as
predominant nosocomial pathogens [8]. The two
most common causes of nosocomial bloodstream
infections were identified as coagulase-negative
staphylococci and S. aureus [8,9]. Methicillin-
resistant S. aureus (MRSA) is now recognised
worldwide as one of the most important nosoco-
mial pathogens [9–13], including in Turkey
[14–16]. The treatment of severe infections caused
by some epidemic strains of MRSA is often
difficult [17].
The aim of this study was to investigate
the epidemiological characteristics and clinical
outcome of bloodstream infections caused by
S. aureus (BSISA). In addition, the clonal relation-
ship among MRSA isolates was analysed by
pulsed-field gel electrophoresis (PFGE).
P A T I E N T S A N D M E T H O D S
Setting
This prospective study was carried out between June 1999 and
June 2001 at Erciyes University Hospital. This hospital is a
tertiary care hospital with 1000 adult beds, including four
intensive care units (ICUs). The study was approved by the
Ethics Committee of the Faculty of Medicine at Erciyes
University.
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Patients
Patients aged > 16 years and diagnosed with BSISA were
enrolled in the study. Patients with signs of infection and ⁄ or
positive blood cultures for S. aureus were evaluated for BSISA by
the same infectious diseases team. Routine laboratory tests, with
radiological investigation if required, and blood and other
sample cultures were performed for all patients. At least two
blood cultures were obtained from each patient. Data recorded
were: age, sex, underlying conditions, all surgical procedures,
foreign body, mechanical ventilation, total parenteral nutrition,
previous antibiotic therapy. The severity of infection was
classified as bacteraemia, sepsis, severe sepsis, or septic shock
according to published recommendations [18]. The patients
were followed until discharged from the hospital. The duration
of hospital stay for patients with BSISA, as well as suppurative
complications and mortality, were also recorded.
Definitions
The Centers for Diseases Control criteria for blood stream
infection (BSI) were modified for the diagnosis of BSISA [19].
Positive blood cultures for S. aureus in a patient were evaluated
as follows:
Primary BSISA
1 One or more positive blood culture(s) for S. aureus, unrelated
to infection at another site;
2 A positive blood culture for S. aureus from a patient’s
intravascular access device, with antimicrobial therapy
initiated by the physician;
3 Intravascular catheter-related infections caused by S. aureus.
Secondary BSISA
When S. aureus isolated from blood culture was compatible with a
related infection at anothersite, the BSI was classified asa secondary
BSISA. The source of secondary BSISA was defined as the site of
infection that was evident clinically at the onset of symptoms and
signs associated with the initial positive blood cultures.
Catheter-related BSISA
When the same S. aureus strain was isolated in blood cultures
and in the semi-quantitative culture of a catheter segment
(yield of ‡ 15 colonies), and if localised signs of infection were
present at the access site, and if no primary site other than the
intravascular catheter could be identified [20].
Nosocomial BSISA
When the positive blood cultures were taken at least 72 h after
admission to the hospital, or within 10 days of discharge.
Community-acquired BSISA
When the positive blood cultures were taken within the first
72 h following admission to the hospital.
Suppurative complication
When a diagnosis of a suppurative complication was made on the
basis of physical examination, pertinent diagnostic evaluation,
and a positive culture for S. aureus from the site involved [21].
Microbiological studies
BACTEC 9240 blood culture systems (Becton Dickinson,
Franklin Lakes, NJ, USA) were used during the study period.
S. aureus isolates were identified by standard microbiological
methods at the Clinical Microbiology Laboratory in Erciyes
University Hospital. Catheter tips were cultured by the
method of Maki et al. [22]. Oxacillin resistance was determined
after incubation for 24 h at 35 C with a 1-lg oxacillin disc,
according to National Committee for Clinical Laboratory
Standards (NCCLS) guidelines [23]. Resistance was reported
if there was growth within a 10-mm zone of inhibition. MRSA
isolates were collected and stored in microbanks at )70 C
until analysed. Confirmation of methicillin resistance was
carried out with the oxacillin agar screening technique,
according to NCCLS guidelines [24].
PFGE analysis
PFGE analysis of 80 MRSA isolates was performed at the
Infectious Diseases Unit, Faculty of Medicine, Hacettepe
University, Ankara, Turkey. Genomic DNA from S. aureus
was prepared as described by de Lencastre et al. [10] and
digested with SmaI (Promega, Madison, WI, USA). The DNA
macrorestriction fragments were separated in agarose (Genax-
is, Spechbach, Germany) 1.1% w ⁄v gels by PFGE (General
Navigator system; Pharmacia, Uppsala, Sweden). A k-ladder
(Sigma, Deisenhofen, Germany) was used for molecular size
markers. Strains showing changes in more than three frag-
ments were assumed to represent different major patterns
(assignment of capital letters), while changes in between one
and three fragments were considered to represent subtypes
(capital letters with numerical subcode) [25].
Statistical analysis
The v2 test, Fisher’s exact v2test, and Student t-tests were used
for statistical analyses; p values < 0.05 were considered to be
statistically significant.
R E S U L T S
This study included 177 patients, of whom 35
(19.8%) had community-acquired BSISA and 142
(80.2%) had nosocomial BSISA. The incidence of
nosocomial BSISA was 2.34 ⁄ 1000 in the study
period. Characteristics of the patients with BSISA
are summarised in Table 1. No significant differ-
ence was found between the groups in terms of
age and underlying diseases. In the community-
acquired BSISA group, diabetes mellitus was
present in 13 (37.1%) patients, cardiovascular
disease in six (17.1%), chronic renal failure in four
(11.4%), cerebrovascular disease in two (5.7%),
and lymphoma, leukaemia and another disease in
one (2.9%) patient each. Five patients each had
two underlying diseases in the community-
acquired BSISA group. In the nosocomial BSISA
group, chronic renal failure was present in 43
(30.3%) patients, cardiovascular disease in 33
(23.2%), diabetes mellitus in 14 (9.9%), chronic
obstructive pulmonary disease in ten (7.0%),
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lymphoma in six (4.2%), cerebrovascular disease
in five (3.5%), leukaemia in four (2.8%), cirrhosis
in two (1.4%), and other rare underlying diseases
in 25 (17.6%) patients. Twenty-three patients had
two underlying conditions, four patients had
three underlying diseases, and one patient
had five underlying diseases.
Surgical intervention, foreign body, mechanical
ventilation and total parenteral nutrition, were
found to be important risk factors for the nosoco-
mial BSISA group. The rate of previous antibiotic
administration in patients with nosocomial BSISA
(52.1%) was also higher than in patients with
community-acquired BSISA (11.4%; p < 0.0001).
Primary BSISA were found in 37.1% of the
community-acquired BSISA group, and in 73.2%
of the nosocomial BSISA group (p 0.0001).
The site of infection could not be determined
for ten (76.9%) of the community-acquired pri-
mary BSISA group, and for 29 (27.9%) of the
nosocomial primary BSISA group. Catheter-rela-
ted BSISA was significantly higher in the nosoco-
mial primary BSISA group (72.1%) than in the
community-acquired primary BSISA group
(23.1%; p 0.0009). While the most frequent source
of infection was the skin and ⁄ or soft tissue
(72.7%) in patients with community-acquired
secondary BSISA, a surgical site (39.5%) was the
most frequent source of infection in the patients
with nosocomial secondary BSISA. When the
patients included in the study were classified
according to severity of infection (Table 2), the
bacteraemia rate for patients with nosocomial
primary BSISA (61.5%) was significantly higher
than for patients with community-acquired pri-
mary BSISA (30.8%; p 0.041).
Two (5.7%) of 35 patients with community-
acquired BSISA were hospitalised in ICUs, with
16 (45.7%) patients in the infectious diseases
clinic, and the remainder in other wards. Acqui-
sition of nosocomial BSISA occurred in ICUs for
71 (50%) of 142 patients, in the nephrology clinic
for 33 (23.2%) patients, and in other wards for the
remaining 38 (26.8%) patients.
The mean length of hospital stay associated with
community-acquired BSISA was 19.7 ± 10.8 days.
The mean extra hospital stay associated with
nosocomial BSISA was 11.8 ± 7.3 days. Of 177
patients, 47 (26.6%) died. Five (14.3%) patients
with community-acquired BSISA, and 20 (14.3%)
with nosocomial BSISA, died because of infection.
Various suppurative complications developed in
17 (9.6%) of 177 patients. The complication rate was
significantly higher for community-acquired infec-
tions (22.9%) than for nosocomial infections (6.3%;
p 0.008). In the community-acquired BSISA group,
skin and ⁄ or soft tissue abscess and pneumonia
were seen in two patients, while cerebral emboli,
septic arthritis, endocarditis, vertebral osteomyeli-
tis, cerebral emboli plus soft tissue abscess, splenic
abscess plus arthritis, and pneumonia plus pleural
empyema were each seen in one patient. In the
nosocomial BSISA group, endocarditis was seen in
four patients, pneumonia in two patients, and skin
Table 1. Characteristics of patients
with bloodstream infections caused
by Staphylococcus aureus Characteristics
Community-acquired
BSISA (n = 35)
n (%)
Nosocomial
BSISA (n = 142)
n (%) Total v2 p
Female 15 (42.9) 68 (47.9) 83 0.119 0.730
Male 20 (57.1) 74 (52.1) 94
Total 35 (19.8) 142 (80.2) 177
Age (years) (mean ± SD)a 48.5 ± 20.1 52.1 ± 30.8 0.512
Underlying disease 23 (65.7) 107 (75.4) 130 0.889 0.346
Surgical intervention – 70 (49.3) 70
Foreign body – 128 (90.1) 128
Mechanical ventilation – 28 (19.7) 28
Total parenteral nutrition – 43 (30.3) 43
Previous antibiotic treatment 4 (11.4) 74 (52.1) 78 17.272 < 0.0001
Primary BSI 13 (37.1) 104 (73.2) 117 14.756 0.0001
Secondary BSI 22 (62.9) 38 (26.8) 60
Primary BSI
Use of catheter 3 (23.1) 75 (72.1) 78 10.395 0.0009
Peritoneal 2 0
Intravascular 1b 75
Secondary BSI
Skin and soft tissue 16 (72.7) 8 (21.1) 24
Musculoskeletal system 5 (22.7) 1 (2.6) 6
Lung 1 (4.5) 13 (34.2) 14
Urinary system – 1 (2.6) 1
Surgical site – 15 (39.5) 15
BSISA, bloodstream infection caused by S. aureus; aStudent t-test; bHickman–Broviac catheter for haemodialysis.
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and ⁄ or soft tissue abscess, cerebral emboli, and
septic arthritis each in one patient. All S. aureus
isolates from the community-acquired BSISA
group were susceptible to methicillin, but 93
(65.5%) of 142 S. aureus isolates from the nosoco-
mial BSISA group were resistant to methicillin.
When 80 MRSA isolates were analysed by
PFGE, ten main clones (A–J) were detected, with
61 (76.3%) of the 80 isolates belonging to clone A,
which contained five different subtypes. Most
ICU isolates (44 of 55) belonged to clone A. Five
clinical isolates belonged to clone B, four to clone
C, three to clone D, two to clone E, and one each
to clones F, G, H, I and J.
D I S C U S S I O N
Staphylococci are frequently isolated as aetiologi-
cal agents of infectious processes, with S. aureus
being the most important human pathogen [6]. In
the 1980s, Gram-positive organisms, including
S. aureus and coagulase-negative staphylococci,
re-emerged as the leading causes of nosocomial
bacteraemia [10,26,27]. Edmond et al. [28] repor-
ted that staphylococci accounted for 47.6% of
10 617 nosocomial episodes of bacteraemia. As
reported by Pittet and colleagues [29], 55%
of 1745 nosocomial BSI were caused by Gram-
positive cocci. In the present study, community-
acquired BSISA accounted for 19.8% of patients,
and nosocomial BSISA for the remaining 80.2%.
This compares with a range of 50.9–86% reported
in other studies [30–32].
The patients most susceptible to staphylococcal
bacteraemia are those with an underlying condi-
tion such as cirrhosis, diabetes mellitus, chronic
obstructive pulmonary disease, congestive heart
failure or renal failure requiring dialysis [33]. In
the present study, 73.4% of BSISA were accom-
panied by one or more underlying diseases, of
which the most frequent were diabetes mellitus,
chronic renal failure and cardiovascular disease.
Severe underlying disease, confinement to bed, a
poor clinical prognosis, prolonged hospital stay,
previous antibiotic therapy, and severe burns
have all been described as risk factors for MRSA
bacteraemia [34].
Staphylococci are the most frequent cause of
foreign device infections. Most nosocomial
staphylococcal bacteraemia is related to intravas-
cular catheter usage [29,35,36], and catheter-
related infection was observed in 72.1% of
patients with nosocomial primary BSISA. Pittet
et al. [29] demonstrated that most nosocomial
staphylococcal BSIs are primary infections, and
Mylotte et al. [37] noted that nosocomial S. aureus
bacteraemias are seen more frequently as pri-
mary infections, while community-acquired bact-
eraemias are mostly secondary. These findings
correlate with those of the present study, and are
possibly associated with the use of foreign
materials, e.g., intravascular catheters. Secondary
S. aureus bacteraemias are commonly a compli-
cation of skin and soft tissue or respiratory tract
infections [34], and the most frequent source of
infection in the present study was skin and soft
tissue for community-acquired secondary BSISA,
and a surgical site for nosocomial secondary
BSISA. Similar results have been reported by
Cunney et al. [27] and Mylotte et al. [36]. In the
present study, sepsis was the clinical condition
defined most frequently for both primary and
secondary community-acquired BSISA. In
contrast to Conterno et al. [30], who reported a
rate of 22%, septic shock was observed in only
one patient from each group.
Table 2. Distribution of BSISA
according to severity of infectionSeverity of
infection
Community-acquired
BSISA (n = 35)
n (%)
Nosocomial
BSISA (n = 142)
n (%) Total v2 p
Primary BSI
Bacteraemia 4 (30.8) 64 (61.5) 68 3.319 0.041
Sepsis 5 (38.5) 33 (31.7) 38 0.03 0.755
Severe sepsis 3 (23.1) 6 (5.8) 9 2.742 0.061
Septic shock 1 (7.7) 1 (1) 2 0.397 0.211
Total 13 (100) 104 (100) 117
Secondary BSI
Bacteraemia 8 (36.4) 15 (39.5) 23 0.057 0.811
Sepsis 13 (59.1) 22 (57.9) 35 0.008 0.928
Severe sepsis 1 (4.5) 1 (2.6) 2 0.158 1.000
Septic shock – – – – –
Total 22 (100) 38 (100) 60
BSISA, bloodstream infection caused by S. aureus.
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Distant infectious metastasis is a major concern
with BSISA. The vertebral column constitutes the
most common site of septic metastasis complica-
ting S. aureus bacteraemia, with an endocarditis
rate of 1.7–18% [34]. The suppurative complica-
tion rate was 22.9% for patients with community-
acquired infections in the present study, possibly
because of delayed diagnosis and antimicrobial
treatment. Cunney et al. [27] reported complica-
tion rates of 53% and 6%, respectively, for
community-acquired and nosocomial episodes
of S. aureus bacteraemia, with infective endocar-
ditis being the most frequent complication. Sim-
ilar high complication rates were reported by
Raad et al. [38] and Libman et al. [21].
The mortality rate is generally low for BSIs
associated with most Gram-positive bacteria, but
the mortality rate for S. aureus bacteraemia is
21–43% [27,31]. Mortality rates for community-
acquired BSISA and nosocomial BSISA were
14.3% and 14.1%, respectively, in the present
study. Other studies of nosocomial S. aureus
bacteraemia have reported mortality rates of
11.9% [39] and 25% [28].
Studies conducted since the late 1970s have
recorded an increasing frequency of methicillin
resistance among strains recovered from hospit-
alised patients. The percentage of MRSA among
all hospitals in the NNIS system rose from 2.1%
in 1975, to 29% in 1991, and to 35% in 1996 [40].
The present study observed a high rate of
methicillin resistance (65%) in nosocomial BSISA,
but all community-acquired BSISA isolates were
susceptible. van Belkum et al. [16] reported that a
major MRSA clone had spread through a large
part of Turkey. The present study identified ten
different clones among 80 isolates typed by
PFGE. Of these isolates, 76.3% belonged to clone
A, and most of these originated from surgical
ICUs. This indicated that general infection control
procedures, such as hand-washing and wound
care, require more emphasis. Epidemiological
studies have revealed that the main reservoir of
MRSA is the patient, including previously col-
onised or infected patients who are readmitted to
the hospital [34]. The main transmission route of
MRSA is from person to person [41]. Although
most MRSA isolates belonged to clone A, the
other nine clones identified might eventually
spread if infection control procedures are not
enforced properly.
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